BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education? (original) (raw)

Molecular diagnosis & therapy, 2015

Abstract

Patients with metastatic colorectal cancer (mCRC) with BRAF mutation (BRAF MT) generally have a poorer prognosis. BRAF MT may also have implications for treatment strategy. Despite this, inclusion of BRAF in routine molecular testing varies. Here we report the frequency of BRAF reporting in the South Australian (SA) mCRC registry reflecting community practice, together with the survival outcomes based on mutation status. The SA population-based mCRC registry was analysed to assess the number of patients where a BRAF MT result was available. The patient characteristics are reported and overall survival was analysed using the Kaplan-Meier method. Of the 3639 patients who have been entered in the registry, only 6.2 % (227) have BRAF MT results available. Of the patients tested, the BRAF MT rate is 12.7 %. The mutation rate was highest in rightsided primary; right colon 23 versus left colon 8.9 % and rectum 7 %. There was no significant difference in median age or male/female proportion...

Timothy Price hasn't uploaded this paper.

Let Timothy know you want this paper to be uploaded.

Ask for this paper to be uploaded.